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Liver Unit, Bambino Gesù Children’s Hospital and Research Institute, Rome, ItalySee Article, pages 501–507Hepatitis C virus (HCV) infection continues to be an important
global health problem. It is estimated that approximately 170
million people worldwide are infected with HCV [1], and
although children are only a small portion of those infected and
the incidence of new infections has decreased in recent years,
HCV still contributes to chronic liver disease in childhood [2].
Currently, transmission occurs mainly during pregnancy or at
delivery, and the transmission rate is low unless the mother is
HIV-coinfected. Pre-natal screening, where done, allows identiﬁ-
cation of infected mothers and early detection of the infection in
their children. Current guidelines recommend testing for HCV-
RNA after 18 months of age (the results being unreliable earlier
in life) [3,4].
What is the natural history of hepatitis C in childhood? Sev-
eral studies have tried to answer this question, but a low num-
bers of children in the majority of them, and the involvement
in some studies of patients referred to tertiary care centres have
made the results of many of these investigations questionable.
Although only a very long-term prospective study on numerically
valid, unselected cohorts of children infected during pregnancy or
at delivery, can provide a proper estimate of the relative propor-
tion of children who progress to end stage liver disease, studies
thus far have clearly shown that children tend to have a much
more benign HCV infection course than adults [5]. It is also clear
that the development of severe liver disease can be accelerated
by the co-occurrence of thalassemia [6], iron overload [6,7], che-
motherapy [8–11], and HIV co-infection [12].
In adults, HCV therapeutic strategies have evolved frommono-
therapywith interferon (IFN) alfa to combination therapywith IFN
alfa and ribavirin (RBV);while in children, because of RBV-associa-
ted adverse effects (i.e. reversible hemolytic anemia, fetal abnor-Journal of Hepatology 20
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transient elastography.malities and fetal death in animal studies), therapeutic strategies
were initially restricted to IFNmonotherapy [4,13]. In recent years,
favourable results with the combination of pegylated (PEG) inter-
feron alfa-2b and RBV have been reported in children [14,15],
and the US Food and Drug Administration (FDA) has recently
approved such combination therapy for use in previously
untreated children with chronic hepatitis C aged 3 years or older.
This approval has been based on the results of the study reported
in this issue of the Journal of Hepatology [16]. In this multicentre
(22 centres in 9 European or American countries), open-label
study, Wirth et al. have evaluated the efﬁcacy and safety of PEG-
IFN-alfa-2b (60 lg/m2/week) plus RBV (15 mg/kg/day) in 107
previously untreated children (3–17 years of age) with chronic
hepatitis C and compensated liver disease [16]. Diagnosis of
chronic hepatitis C was based on the presence of serum anti-HCV
antibodies and HCV-RNA for more than 6 months before treat-
ment, and histological signs of ﬁbrosis or inﬂammatory activity.
Children, with persistently elevated alanine aminotransferase
(ALT) within 1 year before the screening, were also included in
the trial.
The authors do not mention how the infection was acquired.
Based on previous experiences [14,15], patients with genotype
2 or 3 with a low viral load (HCV-RNA less than 600,000 IU/ml)
were treated for 24 weeks, whereas children infected with geno-
type 1 or 4, and genotype 3 with a high viral load (HCV-RNA
greater than 600,000 IU/ml) received 48 weeks of therapy. The
primary endpoint was a sustained virological response (SVR),
deﬁned as the absence of serum HCV-RNA after 24 weeks from
therapy; secondary end-points were rapid virological response
(RVR), deﬁned as undetectable HCV-RNA at week 4 of treatment,
and early virological response (EVR), deﬁned as complete absence
of serum HCV-RNA at week 12 of therapy. Short-term biochemi-
cal outcomes were measured in terms of normalization of serum
ALT levels, whereas histological improvement was not assessed
because a liver biopsy was performed only at diagnosis. The
results showed a high SVR of approximately 90% in children with
genotype 2 or 3, whereas in those with genotype 1 it went down
to 53%. As expected, in the genotype 1 cohort RVR and EVR
strongly predicted SVR, and patients with a low viral load showed
a greater SVR than those with high viral load. Twelve percent of10 vol. 52 j 472–474
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relapses were observed only in genotype 1 infected children. At
the end of treatment, 77% of patients with elevated levels of
ALT at baseline (approximately 47% of total patients) displayed
ALT level normalization, which was associated, in the 79%, of
cases with SVR.
Although during therapy all patients showed at least one
adverse event, these side effects mostly fell in the mild or moder-
ate class. However, a number of cases (28%) of psychiatric side
effects (e.g. anxiety, depression, irritability, insomnia) were
observed, even though antidepressant supportive therapy was
not necessary; 25% of patients required dose reduction of PEG-
IFN-alfa-2b or RBV for anemia, neutropenia, and weight loss,
but only in one patient therapy was discontinued prematurely.
Importantly, during the treatment course, weight loss and growth
inhibition were common in children. Although children who
experienced weight loss showed a partial, compensatory catch-
up-growth after the completion of treatment, the evaluation of
impact and eventual recovery of growth inhibition clearly
requires a long-term follow-up. Interestingly, although a high
SVR (at least 50%) was observed in all age groups between 3
and 17 years, the results show that adolescents (12–17 years)
respond better to combination therapy and have fewer side
effects compared to children (3–11 years). However, despite
these data, the use of combined treatment is advisable, as soon
as possible in children over the age of 3 with a diagnosis of
chronic hepatitis C [4]. Early treatment is also recommendable
to improve the quality of life that appears to be reduced in chil-
dren with chronic hepatitis C with respect to healthy subjects
[17]. Nevertheless, because the long-term effects of PEG-IFN-
alfa-2b plus RBV are still unknown, it is currently impossible to
determine whether in spite of the adverse events, combined ther-
apy may improve the quality of life of the patient especially com-
plete virus eradication is achieved. In addition, a more detailed
study would be needed to determine how schooling affects com-
pliance to the tolerability to treatment.Screening for hig
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Fig. 1. Possible treatment algorithm for combined therapy PEG-IFN-alfa-2b plus RB
Journal of Hepatology 201Some limitations of the study include the open label design, the
small sample size (in spite of the involvement of so many centres
worldwide), and the lackof a further liverbiopsyperformedat least
2 years after completion of treatment. A plausible alternative to
liver biopsy might be the use of abdominal ultrasound (US) for
evaluating steatosis in combination with non-invasive tests
assessing thepresence and eventually the improvement of ﬁbrosis.
As in recent years the use of serum biomarkers of ﬁbrosis, such as
ELF (Enhanced Liver Fibrosis) panel, and transient elastography
(TE) have been proven very useful in detecting liver ﬁbrosis in pae-
diatric non-alcoholic fatty liver disease [18,19], these non-invasive
techniques could also be efﬁciently applied to evaluate the ﬁbrosis
at the beginning and end of treatment with PEG-IFN-alfa-2b plus
RBV in children with chronic hepatitis C.
Another trial has evaluated, with remarkably similar results,
the use of RBV and of the other available PEG-IFN preparation. In
the PEDS-C trial, published in abstract form, 114 children, with
an average age of 10 years (range 5–18), were randomized to
PEG-IFN-alfa-2b (180 lg per 1.73 m squared once a week) plus
RBV (15 mg/kg of body weight daily), or PEG-IFN-alfa-2a alone
[20]. The children were treated for 48 weeks and followed for up
to 76 weeks. The proportion of children who had a sustained viro-
logical response was: 53% for those getting the combination, and
21% for those on monotherapy. Children with HCV genotype 1
had a response rate of 47% if treated with the combination and
17% if treated with monotherapy, while the comparable ﬁgures
for other genotypes were 80% and 36% [20].
This well planned trial suggests a new standard in the thera-
peutic opportunity to treat children with chronic hepatitis C that
is both efﬁcient and rather safe, and that also represents a novel
possible treatment algorithm for these children (Fig. 1). However,
the question arises as whether to this date the treatment of all
children with HCV infection is cost effective. It is probably not,
given the low rate of progression to cirrhosis and the high cost
of the drugs that makes them impossible to use in those veryh-risk children
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countries (e.g., Pakistan) where HCV infection is the highest. For
the time being, it would therefore be advisable to limit the treat-
ment to those children where risk factors for severe liver disease
have been identiﬁed [6–12].
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